Early Antibiotic Exposure in Low-resource Settings Is Associated With Increased Weight in the First Two Years of Life

Elizabeth T. Rogawski, †James A. Platts-Mills, ‡Jessica C. Seidman, §Sushil John, ||Mustafa Mahfuz, *Manjeswori Ulak, ***Sanjaya Shrestha, ††Sajid B. Soof, †††Pablo Penataro Yori, ||||Estomih Mдуma, *Erling Svensen, ††Tahmeed Ahmed, ††Aldo A.M. Lima, ††Zulfiqar Bhutta, ††††Margaret Kosek, ††Dennis Lang, ††Michael Gottlieb, ††Anita Zaidi, ††Gagandeep Kang, ††††Pascal Bessong, ††Eric R. Houpt, and ††Richard L. Guerrant, on behalf of the MAL-ED Network Investigators

ABSTRACT

Objectives: The potential growth-promoting effects of antibiotics are not well understood among undernourished children in environments with high pathogen exposure. We aimed to assess whether early antibiotic exposure duration and class were associated with growth to 2 years of age across 8 low-resource sites in the MAL-ED birth cohort study.

Methods: We followed 1954 children twice per week from birth to 2 years to record maternally reported antibiotic exposures and measure anthropometry monthly. We estimated the associations between antibiotic exposure before 6 months of age and weight-for-age and length-for-age (LAZ) scores to 2 years. We assessed the impact of class-specific exposures and duration, and compared these results to effects of antibiotic exposures after 6 months of age.

Results: Antibiotic use before 6 months of age was associated with increased weight from 6 months to 2 years, whereas associations with length were less consistent across sites and antibiotic classes. Compared to unexposed children, 2 or more courses of metronidazole, macrolides, and cephalosporins were associated with adjusted increases in weight-for-age of 0.24 (95% confidence interval (CI): 0.04, 0.43), 0.23 (95% CI: 0.05, 0.42), and 0.19 (95% CI: 0.04, 0.35) from 6 months to 2 years, respectively.

Conclusions: Antibiotic use in low-resource settings was most associated with the ponderal growth of children who had multiple exposures to antibiotics with broad spectrum and anaerobic activity in early infancy. Opportunities for rational and targeted antibiotic therapy in low resource settings may also promote short-term weight gain in children, although longer-term physical growth and metabolic impacts are unknown.

Key Words: antibiotics, growth, low-resource settings, pediatric enteric disease (JPEN 2017;65: 350–356)

Received January 23, 2017; accepted April 30, 2017.

OPEN

After decades of antibiotic use to promote growth of livestock in the agricultural industry, researchers have begun to explore the potential role of antibiotic use in promoting growth in humans as well as in livestock. While the benefits of antibiotics in livestock production are well understood, the potential for similar growth-promoting effects in humans is less well understood.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.jpenn.org). The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Project (MAL-ED) is carried out as a collaborative project supported by the Bill & Melinda Gates Foundation, the Foundation for the NIH, and the National Institutes of Health/Fogarty International Center. This work was supported by the Fogarty International Center, National Institutes of Health (D43-TW009359 to E.R.R.).

The authors report no conflicts of interest.

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1097/MPG.0000000000001640
well (1). Evidence of the potential for antibiotics to cause long-lasting perturbations of the gut microbiota (2,3) and the role of the microbiota in metabolism (4–6) has suggested that this exposure could be an important research target as a modifiable factor that may be contributing to the obesity epidemic in high-income countries. Antibiotic exposure early in life, during the maturation process of the gut microbiota and enteric immune system, has been hypothesized to have the largest potential impact on growth (6,7). Epidemiologic studies investigating the role of early life antibiotic exposures in high-income settings of Finland (8), United Kingdom (9,10), United States (11,12), The Netherlands (13), and Denmark (14) have shown associations between early antibiotic exposure and child growth standards (25). Length measurements from Pakistan length were measured monthly, and weight-for-age (WAZ) and weight were collected monthly and tested for 40 enteropathogens (24). Weight and height were measured monthly at home visits until 2 years of age to document illnesses, breast-feeding practices, and antibiotic use. Caregivers reported all diarrheal surveillance stool samples were collected from the caregiver of each child.

Data and Definitions

Analysis

We used multivariable linear regression to estimate the association between antibiotic use in the first 6 months of life and monthly WAZ and LAZ from 6 to 24 months of age. Antibiotic exposure was modeled as a continuous measure of duration in days from 0 to 5 months of age and as a categorical variable by number of courses received to assess the potential for a nonlinear dose-response. We also stratified antibiotic effects by sex and site. Generalized estimating equations with robust variance were used to account for correlation between anthropometric measurements within children across time points. Confounding variables for adjustment included baseline characteristics and indicators for treatment, and were selected by causal diagram (26) based on expert opinion and a previous analysis of factors associated with antibiotic use in MAL-ED (22). All analyses were adjusted for site, child sex, enrollment WAZ, WAMI score, crowding (people/room in household), maternal height, maternal education, and characteristics of the child’s first 6 months of life: percent days exclusively breast-fed; number of diarrhea episodes; days with fever, vomiting, and respiratory illness; and presence of acute lower respiratory infection, bloody stools, and hospitalization. Length models also included enrollment LAZ. We further explored the effects of class-specific antibiotic exposure use by modeling class-specific exposure as dichotomous (exposed to a specific class on at least 1 day vs not) and as a categorical variable by number of class-specific courses received, using the models above and additionally adjusting for other antibiotic class exposures to isolate class-specific effects. We also explored effect measure modification by malnutrition (stunted and underweight) at 6 months and pathogen burden from 0 to 5 months (presence of Campylobacter, enteraggregative Escherichia coli, and Giardia, and average number of bacterial pathogens detected (24)) by including interaction terms between the exposures and these variables and estimating subgroup-specific effects.

To compare early life exposures with later exposures, we used linear regression to estimate the effects of exposures from 0 to 6 months of age on adult weight and height. Based on expert opinion and a previous analysis of factors associated with adult measures in MAL-ED (18), we adjusted for indicators of wealth (26). All analyses were adjusted for site, sex, and age at last follow-up. For height and weight, we also adjusted for adult height and weight, and z-scores were calculated using the 2006 WHO child growth standards (25).

We used multivariable linear regression to estimate the association between antibiotic use in the first 6 months of life and monthly WAZ and LAZ from 6 to 24 months of age. Antibiotic exposure was modeled as a continuous measure of duration in days from 0 to 5 months of age and as a categorical variable by number of courses received to assess the potential for a nonlinear dose-response. We also stratified antibiotic effects by sex and site. Generalized estimating equations with robust variance were used to account for correlation between anthropometric measurements within children across time points. Confounding variables for adjustment included baseline characteristics and indicators for treatment, and were selected by causal diagram (26) based on expert opinion and a previous analysis of factors associated with antibiotic use in MAL-ED (22). All analyses were adjusted for site, child sex, enrollment WAZ, WAMI score, crowding (people/room in household), maternal height, maternal education, and characteristics of the child’s first 6 months of life: percent days exclusively breast-fed; number of diarrhea episodes; days with fever, vomiting, and respiratory illness; and presence of acute lower respiratory infection, bloody stools, and hospitalization. Length models also included enrollment LAZ. We further explored the effects of class-specific antibiotic exposure use by modeling class-specific exposure as dichotomous (exposed to a specific class on at least 1 day vs not) and as a categorical variable by number of class-specific courses received, using the models above and additionally adjusting for other antibiotic class exposures to isolate class-specific effects. We also explored effect measure modification by malnutrition (stunted and underweight) at 6 months and pathogen burden from 0 to 5 months (presence of Campylobacter, enteraggregative Escherichia coli, and Giardia, and average number of bacterial pathogens detected (24)) by including interaction terms between the exposures and these variables and estimating subgroup-specific effects.

To compare early life exposures with later exposures, we used linear regression to estimate the effects of exposures from 0 to 6 months of age on adult weight and height. Based on expert opinion and a previous analysis of factors associated with adult measures in MAL-ED (18), we adjusted for indicators of wealth (26). All analyses were adjusted for site, sex, and age at last follow-up. For height and weight, we also adjusted for adult height and weight, and z-scores were calculated using the 2006 WHO child growth standards (25).
24 months on cross-sectional WAZ and LAZ at 2 years. A child’s measurement closest to 24 months, between 23 and 25 months was considered their anthropometry at 2 years. Adjustment variables included the same baseline characteristics as above, including enrollment WAZ, enrollment LAZ (for length models only), illness burden as characterized above the whole 2 years of follow-up, and antibiotic use in the first 6 months of life. Using these models with cross-sectional outcomes of WAZ and LAZ at 2 years, we demonstrated that the early life effects were insensitive to further statistical adjustment for illnesses and antibiotic use after 6 months of age.

RESULTS

Across 8 sites in the MAL-ED cohort, 1954 children were followed until at least 6 months of age and had at least 1 subsequent anthropometric measurement. The majority of these children (n = 1736, 88.3%) remained under surveillance and had anthropometric measurements at 2 years. Baseline characteristics, early antibiotic exposure, and growth outcomes differed across sites (Table 1), with the highest antibiotic use in the South Asian sites (22). Mean enrollment weight and length within 17 days of birth across sites were near 1 standard deviation below the WHO standard. All sites except Brazil showed reductions in average WAZ and LAZ over the 2 years of follow-up with overall means at 2 years of −1.06 and −1.71, respectively.

A 7-day increase in duration of antibiotic exposure in the first 6 months of life was associated with an adjusted 0.03 (95% confidence interval [CI]: 0.00, 0.05) higher WAZ from 6 months to 2 years of age compared to unexposed children. There was no difference between boys and girls, and this association was largely consistent across sites, except in Brazil and South Africa, where antibiotic use was least common and the estimates are least precise (Fig. 1A). The largest differences in WAZ were associated with children who received >3 courses in the first 6 months (Supplemental Digital Content 2, Fig. 2A, http://links.lww.com/MPG/B14). Children who received >3 courses of antibiotics in the first 6 months of life had an average 0.18 (95% CI: 0.06, 0.30) higher WAZ from 6 months to 2 years compared to children receiving 3 courses or less. This effect was largest in Pakistan (WAZ difference: 0.46, 95% CI: 0.25, 0.67) and Tanzania (WAZ difference: 0.21, 95% CI: −0.01, 0.43), but these estimates translate to relatively small differences in weight (600 and 280 g at 2 years, respectively).

The associations of duration of antibiotic exposure with LAZ were more varied across sites (Fig. 1B). There was no difference in LAZ between children exposed to between 0 and 4 courses of antibiotics. Children exposed to 5 or more courses of antibiotics before 6 months had a slightly higher but nonsignificant increase in LAZ compared to unexposed children (Fig., Supplemental Digital Content 2, Fig. 2B, http://links.lww.com/MPG/B14).

### Table 1. Baseline characteristics and antibiotic use by site among 1954 children in the MAL-ED cohort who were followed until at least 6 months of age with subsequent anthropometry

| Site               | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        |
|--------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Dhaka, Bangladesh  | 240 (60.8)                     | 89 (65.3)                      | 178 (72.5)                     | 164 (62.6)                     | 111 (45.8)                     | 190 (62.3)                     | 135 (49.7)                     |
| Fortaleza, Brazil  | 207 (50.8)                     | 123 (63.3)                     | 99 (47.4)                      | 128 (60.8)                     | 107 (52.3)                     | 129 (59.8)                     | 124 (50.6)                     |
| Vellore, India     | 234 (56.9)                     | 27 (13.0)                      | 227 (96.2)                     | 225 (93.8)                     | 228 (92.6)                     | 230 (93.2)                     | 223 (91.0)                     |
| Bhakatpur, Nepal   | 235 (57.4)                     | 82 (35.3)                      | 109 (46.4)                     | 185 (79.0)                     | 100 (39.6)                     | 136 (51.3)                     | 371 (19.0)                     |
| Loreto, Peru       | 269 (67.3)                     | 60 (25.5)                      | 235 (94.4)                     | 100 (37.2)                     | 105 (41.5)                     | 129 (49.8)                     | 123 (45.7)                     |
| Naushahro, Pakistan| 269 (67.7)                     | 60 (22.3)                      | 123 (53.7)                     | 105 (37.2)                     | 105 (40.6)                     | 129 (49.8)                     | 136 (51.3)                     |
| Venda, South Africa| 259 (66.0)                     | 60 (22.3)                      | 123 (53.7)                     | 105 (37.2)                     | 105 (40.3)                     | 129 (49.8)                     | 123 (45.7)                     |
| Haydom, Tanzania   | 265 (74.1)                     | 60 (22.3)                      | 123 (53.7)                     | 105 (37.2)                     | 105 (40.6)                     | 129 (49.8)                     | 123 (45.7)                     |
| Overall            | 261 (68.0)                     | 60 (22.3)                      | 123 (53.7)                     | 105 (37.2)                     | 105 (40.6)                     | 129 (49.8)                     | 123 (45.7)                     |

At least 1 day of class-specific antibiotic exposure before 6 mo

| Antibiotic           | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        | No. (%)                        |
|----------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Penicillins          | 202 (84.2)                     | 61 (60.0)                      | 173 (64.3)                     | 151 (57.0)                     | 59 (22.8)                      | 150 (61.2)                     | 907 (46.4)                     |
| Cephalosporins       | 158 (65.8)                     | 62 (26.5)                      | 27 (11.5)                      | 205 (77.4)                     | 1 (0.4)                        | 2 (0.8)                       | 493 (25.2)                     |
| Macrolides           | 143 (59.6)                     | 28 (11.9)                      | 86 (32.6)                      | 79 (29.8)                      | 7 (2.7)                        | 6 (2.5)                       | 371 (19.0)                     |
| Metronidazole        | 8 (3.3)                       | 37 (57.7)                      | 2 (0.7)                        | 156 (58.9)                     | 3 (1.2)                        | 59 (24.1)                     | 276 (14.1)                     |
| Sulfonamides         | 3 (1.3)                       | 19 (8.1)                       | 45 (16.7)                      | 73 (27.6)                      | 10 (3.9)                       | 55 (22.5)                     | 228 (11.7)                     |
| Fluoroquinolones     | 34 (14.2)                      | 4 (1.7)                        | 17 (5.5)                       | 222 (83.8)                     | 4 (1.5)                        | 65 (26.5)                     | 602 (30.8)                     |

*Table 1 is continued.*

---

**Notes:**

- EAEC = enteroaggregative E. coli; IQR = interquartile range; LAZ = length-for-age z score; USD = United States Dollars; WAZ = weight-for-age z score.
- *Within 17 days of birth.
In the assessment of class-specific exposure, macrolide and metronidazole use on at least 1 day during the first 6 months were associated with an adjusted 0.14 (95% CI: 0.02, 0.25) and 0.17 (95% CI: 0.04, 0.31) increase in WAZ, respectively. Cephalosporins, fluoroquinolones, and penicillins were associated with smaller and nonsignificant increases in WAZ. Associations with LAZ were generally smaller and not statistically significant for any antibiotic class (Table 2). Although the effects of macrolides and cephalosporins were close to null if only 1 course was received, 2 or more courses were associated with an adjusted increase of 0.23 (95% CI: 0.05, 0.42) and 0.19 (95% CI: 0.04, 0.35) in WAZ, respectively (Table 2). Metronidazole was associated with increases in WAZ both when children were exposed to only 1 course (WAZ difference: 0.14, 95% CI: −0.00, 0.29) and 2 or more courses were associated with an adjusted increase of 0.23 (95% CI: 0.05, 0.42). In contrast, a dose-response pattern was absent for the effects on LAZ, except for cephalosporins, in which 2 or more courses of cephalosporins were associated with a 0.19 (95% CI: 0.01, 0.37) increase in LAZ (Table 2). There was no statistical evidence for effect measure modification by malnutrition or pathogen burden in surveillance stools (not shown).

The weight and length increases associated with antibiotic use before 6 months of age occurred during the exposure window and up to 1 year later at 18 months of age. By 6 months, children who were exposed to >3 courses of antibiotics had a 0.09 (95% CI: −0.04, 0.22) greater WAZ compared to children receiving 3 courses or less (Supplemental Digital Content 3, Fig. 3A, http://links.lww.com/MPG/B15). These children had further gains of 0.08 (95% CI: −0.06, 0.06) and 0.04 (95% CI: −0.02, 0.05) in WAZ compared to children receiving 3 courses or less from 6 to 11 and 12 to 17 months, respectively. Adjusting for their WAZ at 18 months, there was no further difference in WAZ from 18 to 24 months associated with early antibiotic use (WAZ difference: 0.00, 95% CI: −0.04, 0.05). Children who did not, however, receive early antibiotics did not catch-up during this period such that the majority of the overall

### TABLE 2. Adjusted weight-for-age and length-for-age z score differences associated with class-specific antibiotic use in the first 6 months of life among 1954 children in the MAL-ED birth cohort

| Antibiotic class exposure in first 6 months of life | Number exposed (%) | Adjusted WAZ difference (95% CI) | Number exposed (%) | Adjusted LAZ difference (95% CI) |
|---------------------------------------------------|--------------------|----------------------------------|--------------------|----------------------------------|
| Metronidazole                                     |                    |                                  |                    |                                  |
| 1 Course                                          | 170 (8.7)          | 0.14 (−0.01, 0.29)               | 109 (6.5)          | 0.00 (−0.15, 0.16)               |
| 2+ Courses                                        | 106 (5.4)          | 0.24 (0.04, 0.43)                | 11 (0.7)           | 0.02 (−0.35, 0.40)               |
| Macrolides                                        |                    |                                  |                    |                                  |
| 1 Course                                          | 258 (13.2)         | 0.09 (−0.03, 0.21)               | 206 (12.2)         | 0.07 (−0.05, 0.18)               |
| 2+ Courses                                        | 114 (5.8)          | 0.23 (0.05, 0.42)                | 87 (5.2)           | −0.00 (−0.20, 0.19)              |
| Cephalosporins                                    |                    |                                  |                    |                                  |
| 1 Course                                          | 244 (12.5)         | 0.03 (−0.09, 0.16)               | 182 (10.8)         | 0.02 (−0.11, 0.14)               |
| 2+ Courses                                        | 249 (12.7)         | 0.19 (0.04, 0.35)                | 106 (6.3)          | 0.19 (0.01, 0.37)                |
| Penicillins                                       |                    |                                  |                    |                                  |
| 1 Course                                          | 450 (23.0)         | 0.09 (−0.02, 0.19)               | 382 (22.6)         | −0.04 (−0.13, 0.06)              |
| 2+ Courses                                        | 457 (23.4)         | 0.07 (−0.04, 0.18)               | 373 (22.1)         | −0.00 (−0.11, 0.10)              |
| Fluoroquinolones (any)                            | 66 (3.4)           | 0.08 (−0.14, 0.30)               | 57 (3.4)           | 0.05 (0.16, 0.27)                |
| Sulfonamides (any)                                 | 228 (11.7)         | 0.03 (−0.09, 0.15)               | 155 (9.2)          | −0.02 (−0.14, 0.11)              |

LAZ = length-for-age z score; WAZ = weight-for-age z score.

1 Adjusted for other antibiotic classes included in the table, site, child sex, enrollment WAZ, Water, Assets, Maternal education, Income (WAMI) score, crowding (people/room in household), maternal height, maternal education, and characteristics of the child’s first 6 months of life: percent days exclusively breast-fed; number of diarrhea episodes; days with fever, vomiting, and respiratory illness; and presence of acute lower respiratory infection (ALRI), bloody stools, and hospitalization. LAZ difference is also adjusted for enrollment LAZ.

2 Children who were followed in the MAL-ED birth cohort until at least 6 months of age with subsequent anthropometry. LAZ difference estimates exclude Pakistan.
WAZ difference was maintained to 24 months. More than 3 courses of antibiotics was associated with a similar increase in LAZ by 6 months (0.08, 95% CI: −0.05, 0.21), but there were no associations in periods after 6 months (Supplemental Digital Content 3, Fig. 3B, http://links.lww.com/MPG/B15) or overall as shown above.

In contrast to the antibiotic effects in early infancy, duration of antibiotic exposure after 6 months of age were not associated with cross-sectional WAZ or LAZ at 2 years (Supplemental Digital Content 4, Table, http://links.lww.com/MPG/B16), adjusting for exposure before 6 months and illnesses across the first 2 years of life. Among the antibiotic classes, only fluoroquinolones were associated with increases in size at 2 years of age. Two or more courses of fluoroquinolones after 6 months of age were associated with an adjusted increase of 0.21 (95% CI: 0.05, 0.37) in WAZ at 2 years (Supplemental Digital Content 4, Table, http://links.lww.com/MPG/B16). The associations with other antibiotic classes were near the null and/or did not show a dose-response trend.

**DISCUSSION**

We demonstrate that the growth-promoting phenomenon of early life antibiotic exposure among healthy children is not unique to high-resource settings and can also occur in populations with low average weights and lengths. Antibiotic exposure was associated with increases in weight in the MAL-ED cohort, and this effect was limited to early exposures in the first 6 months of life, which is consistent with previous studies (8,9,13,14). Associations of antibiotics with length were generally smaller and inconsistent across sites and drug classes. The greatest increases in WAZ were associated with ≥3 courses of exposure and when multiple treatment courses of macrolides, metronidazole, and cephalosporins were received.

A larger impact of macrolides compared to other antibiotics on BMI was similarly documented in a retrospective US study (12). Broad-spectrum antibiotics were associated with early childhood obesity in the United States, whereas narrow-spectrum antibiotics (penicillins) were not (11). Two previous trials of metronidazole treatment in the general pediatric population in Guatemala (1982) (29) and in malnourished children in Jamaica (1993) (30) found an association between metronidazole and improved growth. Although metronidazole is considered narrow-spectrum, its anaerobic activity may be particularly destructive to the gut microbiota. Antibiotics with anaerobic activity have been associated with growth in a dose-dependent manner in the United Kingdom, whereas antibiotics without anaerobic activity were not (10).

Our results provide support for the hypothesized mechanism through the gut microbiota. The influence of antibiotics on the diversity and composition of the gut microbiota can persist long after treatment is completed (2,31), especially among infants (32,33). Altered microbiota can modify metabolism and intestinal inflammation and immunity resulting in increased energy harvest from the diet (4,6,54). Murine models suggest a causal association between the microbiota and obesity; when antibiotic-altered microbiota from overweight mice were transferred to germ-free mice, these mice experienced the same growth and immune response phenotypes as the donor mice (6).

Because the effect of early life antibiotics did not, however, affect growth rates after 18 months of age, the impact of an altered microbiota may be short lived. This evidence that the microbiota is not necessarily permanently “reprogrammed” to cause increased growth rates long after exposure is supported by a recent large study in the United States that found that early antibiotic use was not associated with higher rates of weight gain after the exposure period (15). Their results may be explained by their analytic exclusion of antibiotic-induced weight gain during the exposure period. Taken together, the evidence suggests that short-term boosts in growth due to antibiotics may be more relevant than long-term changes in growth rates.

Still, because the unexposed children in the MAL-ED cohort did not complete catch-up growth, such that the weight difference associated with antibiotic exposure was still present at 24 months, these exposures may have sustained impact on a child’s attained size. Short-term growth and attained size have been negatively associated with hospitalization and mortality (35), and positively with cognitive outcomes such as IQ, years of schooling, and income (36), respectively. The first 2 years of life are an especially critical period (37), and even modest improvements in weight gain during this time may be beneficial. Increased relative weight gain in the first 2 years of life, beyond what was expected from linear growth, was, however, not associated with improvements in human capital in Brazil (36), which suggests linear growth may ultimately be more important for long-term cognitive outcomes.

The observed effects limited to exposure in the first 6 months suggest that antibiotic-related modifications of the microbiota, which are most detrimental early in microbiota development, may be more important than clearance of bacterial enteropathogens, which increase in prevalence across the first 2 years of life. If treatment of infections were the main mechanism, we would expect antibiotic exposure after 6 months of age to also have an impact. Furthermore, we did not find that children with more bacterial pathogens before 6 months of age had larger improvements in WAZ associated with antibiotics than those without bacterial pathogens. Pathogen prevalence in the MAL-ED study was, however, high, especially for *Campylobacter* and enteraggregative *E coli* in the first 6 months of life (38,39), and clearance of enteropathogens may also be contributing to improved growth in these children. Direct analysis of the microbiome in antibiotic exposed and unexposed children would clarify growth-promoting mechanisms.

This analysis improves on previous studies of the relationship between antibiotics and child growth in low-resource settings. The cross-sectional study conducted in 5 nonaffluent countries (Nigeria, India, Indonesia, Thailand, and Syria) relied on caregiver recall of antibiotic exposures at a minimum of 4 years after exposure and caregiver report of anthropometry (21). A previous analysis of an observational birth cohort in India was unable to assess antibiotic class and had partially missing information on antibiotics for nondiarrheal illnesses (40). A systematic review of randomized controlled trials in low- and middle-income countries only assessed antibiotic treatment for trial-specific indications and did not consider cumulative antibiotic exposure in early life (41). In contrast, MAL-ED included prospective follow-up for complete antibiotic information and monthly anthropometry measurement by trained fieldworkers.

This analysis was limited by the inability to assess long-term growth outcomes 5 to 10 years after exposure. This may explain why there was no observable effect of antibiotic exposure after 6 months of age, which may only become apparent later in childhood (9,12,14). This may also explain why the effects on length were smaller since length represents a longer-term growth process. In addition, the precision of estimates was highly dependent on frequency of use, which varied for different antibiotic classes across sites. Because MAL-ED was an observational study, we cannot eliminate the potential for unmeasured confounding, for example, by mode of delivery, which was not recorded. Our analyses, however, accounted for factors associated with antibiotic use previously identified in MAL-ED (22) and each child’s detailed illness history. Because we would expect children with more illnesses to be exposed to more antibiotics and have poorer growth, residual confounding by illnesses would likely bias our estimates toward the null, such that our estimates would be conservative.
An association between antibiotics and weight gain in high-income settings is often discussed as a negative side effect of treatment since obesity is a growing public health problem and particularly pernicious among children. The cost-benefit analysis may, however, be different in low-resource settings where children may benefit from improvements in growth and are commonly infected with enteropathogens even in the absence of diarrhea (38). On the contrary, overuse of antibiotics is a major concern worldwide and can lead to adverse events, drug toxicity, and antimicrobial resistance. Antibiotic exposure can also cause antibiotic-associated diarrhea (42), alter intestinal immune function, increase intestinal permeability, and increase risk of systemic infections and subsequent diarrhea (32,43–46). Furthermore increased weight gain may not be an unmitigated positive if antibiotic-induced changes to the microbiota lead to increased risk for obesity or metabolic syndrome later in life (6). It is unknown whether antibiotic-induced weight gain in these settings is equivalent in terms of developmental impact to similar gains achieved by appropriate nutrition and illness management. Therefore, the total impact of antibiotic exposure early in life among children in low-resource settings is unknown and may be mixed. Reduction of inappropriate antibiotic use must be a public health priority, although opportunities for rational and targeted antibiotic therapy may provide additional benefit by promoting weight gain in these children.

Acknowledgments: The authors thank the staff and participants of the MAL-ED Network Project for their important contributions. The MAL-ED Network Investigators include representatives from the following organizations: A.B. PRISMA, Iquitos, Peru; Aga Khan University, Karachi, Pakistan; Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Christian Medical College, Vellore, India; Duke University, Durham, NC; Fogarty International Center/National Institutes of Health, Bethesda, MD; Foundation for the NIH, Bethesda, MD; Haydom Lutheran Hospital, Haydom, Tanzania; icddr,b, Dhaka, Bangladesh; Institute of Medicine, Tribhuvan University, Kathmandu, Nepal; Johns Hopkins University, Baltimore, MD; The Pennsylvania State University, University Park, PA; Temple University, Philadelphia, PA; Universidade Federal do Ceará, Fortaleza, Brazil; University of Bergen, Norway; University of Illinois at Chicago, IL; University of Venda, Thohoyandou, South Africa; University of Virginia, Charlottesville, VA; Walter Reed AFRIMS Research Unit, Kathmandu, Nepal; Haukeland University Hospital, Bergen, Norway. A complete list of investigators is included in the Supplemental Digital Content 1, Text, http://links.lww.com/MPGB/B13.

REFERENCES
1. Lin J. Effect of antibiotic growth promoters on intestinal microbiota in food animals: a novel model for studying the relationship between gut microbiota and human obesity? Front Microbiol 2011;2:53.
2. Jernberg C, Löflmark S, Edlund C, et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology (Reading, Engl) 2010;156(pt 11):3216–23.
3. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011;108(suppl 1):4554–61.
4. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718–23.
5. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
6. Cox LM, Yamashita S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705–21.
7. Martin R, Nauta AJ, Ben Amor K, et al. Early life: gut microbiota and immune development in infancy. Benef Microbes 2010;1:367–82.
8. Saari A, Virta LJ, Sankkampi U, et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics 2015;135:617–26.
9. Trasande L, Blustein J, Liu M, et al. Infant antibiotic exposures and early-life body mass. Int J Obes 2013;37:16–23.
10. Schwartz BS, Pollak J, Bailey-Davis L, et al. Antibiotic use and childhood body mass index trajectory. Int J Obes (Lond) 2016;40:615–21.
11. Mbagwa CA, Scheres L, Penders J, et al. Early life antibiotic exposure and weight development in children. J Pediatr. http://www.sciencedirect.com/science/article/pii/S0022347616307574. Accessed July 19, 2016.
12. Schwartz BS, Pollak J, Bailey-Davis L, et al. Antibiotic use and childhood body mass index trajectory. Int J Obes (Lond) 2016;40:615–21.
13. Mbakwa CA, Scheres L, Penders J, et al. Early life antibiotic exposure and weight development in children. J Pediatr. http://www.sciencedirect.com/science/article/pii/S0022347616307574. Accessed July 19, 2016.
14. Ajslev TA, Andersen CS, Gamborg M, et al. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond) 2011;35:522–9.
15. Gerber JS, Bryan M, Ross KK, et al. Antibiotic exposure during the first 6 months of life and weight gain during childhood. JAMA 2016;315:1258–65.
16. WHO. Guideline: Updates on the management of severe acute malnutrition in infants and children [Internet]. Geneva: World Health Organization; 2013. http://www.who.int/nutrition/publications/guidelines/updates_management_SERVING万物/children/en.
17. Trehan I, Goldbach HS, LaGronne LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013;368:425–35.
18. Isanaka S, Langendorg C, Berthel F, et al. Routine amoxicillin for uncomplicated severe acute malnutrition in children. N Engl J Med 2016;374:444–53.
19. Angelakis E, Merhej V, Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet Infect Dis 2013;13:889–99.
20. Million M, Lagier J-C, Yahav D, et al. Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013;19:305–13.
21. Murphy R, Stewart AW, Brathwaithe L, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes (Lond) 2013;38:1115–9.
22. Rogowski EF, Platts-Mills JA, Seidman JC, et al. Use of antibiotics in children younger than two years in eight countries: a prospective cohort study. Bull World Health Organ 2017;95:49–61.
23. MAL-ED Network Investigators. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. Clin Infect Dis 2014;59(suppl 4):S193–206.
24. Houpert E, Gratzi J, Kosek M, et al. Microbiologic methods utilized in the MAL-ED cohort study. Clin Infect Dis 2014;59(suppl 4):S225–32.
25. World Health Organization. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age, Methods and development. 2006. http://www.who.int/childgrowth/standards/Technical_report.pdf?ua=1. Accessed May 9, 2016.
26. Psaki SR, Seidman JC, Miller M, et al. Measuring socioeconomic status in multicitycountrystudies:resultsfromtheeight-countryMAL-EDstudy. Population Health Metrics 2014;12:8.
27. Richard SA, Barrett LJ, Guerlant RL, et al., MAL-ED Network Investigators. Disease surveillance methods used in the 8-site MAL-ED cohort study. Clin Infect Dis 2014;59(suppl 4):S220–4.
28. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37–48.
29. Gupta MC, Urttia JJ. Effect of periodic antiscars and antigandia treatment on nutritional status of preschool children. Am J Clin Nutr 1982;36:79–86.
30. Heikens GT, Schofield WN, Dawson S. The Kingston Project. II. The effects of high energy supplement and metronidazole on malnourished children rehabilitated in the community: anthropometry. Eur J Clin Nutr 1993;47:60–73.

www.jpgn.org

355
31. Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* 2008;6:e280.

32. Faa G, Gerosa C, Fanni D, et al. Factors influencing the development of a personal tailored microbiota in the neonate, with particular emphasis on antibiotic therapy. *J Matern Fetal Neonatal Med* 2013;26(suppl 2):35–43.

33. Saavedra JM, Dattilo AM. Early development of intestinal microbiota: implications for future health. *Gastroenterol Clin North Am* 2012;41:717–31.

34. Cox LM, Blaser MJ. Pathways in microbe-induced obesity. *Cell Metab* 2013;17:883–94.

35. Victora CG, Barros FC, Horta BL, et al. Short-term benefits of catch-up growth for small-for-gestational-age infants. *Int J Epidemiol* 2001;30:1325–30.

36. Horta BL, Victora CG, De Mola CL, et al. Associations of linear growth and relative weight gain in early life with human capital at 30 years of age. *J Pediatr* 2017;182:85.e3–91.e3.

37. Victora CG, Adair L, Fall C, et al. Maternal and child undernutrition: consequences for adult health and human capital. *Lancet* 2008;371:340–57.

38. Platts-Mills TA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). *Lancet Glob Health* 2015;3:e564–75.

39. Amour C, Gratz J, Mduma E, et al. Epidemiology and impact of *Campylobacter* infection in children in eight low-resource settings: results from the MAL-ED study. *Clin Infect Dis* 2016;63:1171–9.

40. Rogawski ET, Westreich DJ, Adair LS, et al. Early life antibiotic exposure is not associated with growth in young children of Vellore, India. *J Pediatr* 2015;167:1096.e3–102.e3.

41. Gough EK, Moodie EEM, Prendergast AJ, et al. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2014;348:g2267.

42. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. *Future Microbiol* 2008;3:563–78.

43. Wlofsarska M, Finlay BB. Host immune response to antibiotic perturbation of the microbiota. *Mucosal Immunol* 2010;3:100–3.

44. Ryan CA, Nichols MK, Hargrett-Bean NT, et al. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. *JAMA* 1987;258:3269–74.

45. Rogawski ET, Westreich DJ, Becker-Deeps S, et al. Antibiotic treatment of diarrhoea is associated with decreased time to the next diarrhoea episode among young children in Vellore, India. *Int J Epidemiol* 2015;44:978–87.

46. Rogawski ET, Westreich D, Becker-Deeps S, et al. The effect of early life antibiotic exposures on diarrheal rates among young children in Vellore, India. *Pediatr Infect Dis J* 2015;34:583–8.